Edition:
United Kingdom

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

8.78USD
21 Sep 2018
Change (% chg)

$0.72 (+8.93%)
Prev Close
$8.06
Open
$8.04
Day's High
$8.92
Day's Low
$7.91
Volume
543,645
Avg. Vol
193,051
52-wk High
$9.86
52-wk Low
$3.31

Latest Key Developments (Source: Significant Developments)

Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15
Wednesday, 2 May 2018 

May 2 (Reuters) - Marinus Pharmaceuticals Inc ::MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND FIRST QUARTER 2018 FINANCIAL RESULTS.MARINUS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.15.MARINUS PHARMACEUTICALS INC - AT MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $52.0 MILLION, COMPARED TO $58.4 MILLION AT DECEMBER 31, 2017.MARINUS PHARMACEUTICALS -BELIEVES THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS, AS OF MARCH 31, 2018, ARE ADEQUATE TO FUND ITS OPERATIONS INTO 2020.  Full Article

Marinus Pharmaceuticals files for mixed shelf of up to $200 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​.  Full Article

Marinus Pharmaceuticals qtrly loss per share $0.15‍​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Marinus Pharmaceuticals Inc :Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results.Marinus Pharmaceuticals Inc - ‍"believes" cash, cash equivalents and investments as of Sept 30, 2017 are adequate to fund operations into 2020​.Marinus Pharmaceuticals Inc qtrly loss per share $0.15‍​.Marinus-Initiating Phase 2 feasibility study with ganaxolone iv in patients with refractory status epilepticus, data expected in 2018‍​.  Full Article

BRIEF-Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15

* MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND FIRST QUARTER 2018 FINANCIAL RESULTS